Adding a PD-1 inhibitor to PARP inhibitor maintenance therapy failed to slow progression or improve survival in newly ...

The efficacy of rucaparib plus nivolumab was compared with rucaparib monotherapy as maintenance treatment for ovarian cancer.

Clovis CEO Patrick Mahaffy “The comprehensive ARIEL3 results presented for the first time today demonstrate the potential of rucaparib to extend the time during which the disease is controlled ...

Research presented at ESMO 2024 could have practice-changing implications for breast, gastrointestinal, genitourinary, and gynecologic cancers.

There is a wide selection of therapies available for advanced prostate cancer treatment, but the optimal strategy for them is ...

The new indication would also extend Lynparza's lead in prostate cancer over rival PARP inhibitors like Clovis Oncology's Rubraca (rucaparib), GSK's Zejula (niraparib) and Pfizer's Talzenna ...

Rucaparib is recommended, within its marketing authorisation, as an option for the maintenance treatment of relapsed platinum-sensitive high-grade epithelial, ovarian, fallopian tube or primary ...

EASD 2024 'Remarkable' Weight Loss With Novel Oral Combo in Phase 1 Amycretin, a dual pathway, oral weight loss drug, was found to be safe and tolerable in a phase 1 study and led to weight loss ...

Sep. 17, 2024 — A key step toward reusing CO2 to make sustainable fuels is chaining carbon atoms together, and an artificial photosynthesis system can bind two of ... Using Sunlight to Turn Two ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial ...

The Israeli government did not tamper with the Hezbollah devices that exploded, defense and intelligence officials say. It manufactured them as part of an elaborate ruse. By Sheera FrenkelRonen ...